Literature DB >> 29471120

The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application to 18F-Radiolabeling.

Cesar Gonzalez1, Andersson Sanchez1, Jeffrey Collins2, Ksenia Lisova3, Jason T Lee2, R Michael van Dam3, M Alejandro Barbieri4, Cheppail Ramachandran5, Stanislaw F Wnuk6.   

Abstract

The coupling of gemcitabine with functionalized carboxylic acids using peptide coupling conditions afforded 4-N-alkanoyl analogues with a terminal alkyne or azido moiety. Reaction of 4-N-tosylgemcitabine with azidoalkyl amine provided 4-N-alkyl gemcitabine with a terminal azido group. Click reaction with silane building blocks afforded 4-N-alkanoyl or 4-N-alkyl gemcitabine analogues suitable for fluorination. RP-HPLC analysis indicated better chemical stability of 4-N-alkyl gemcitabine analogues versus 4-N-alkanoyl analogues in acidic aqueous conditions. The 4-N-alkanoyl gemcitabine analogues showed potent cytostatic activity against L1210 cell line, but cytotoxicity of the 4-N-alkylgemcitabine analogues was low. However, 4-N-alkanoyl and 4-N-alkyl analogues had comparable antiproliferative activities in the HEK293 cells. The 4-N-alkyl analogue with a terminal azide group was shown to be localized inside HEK293 cells by fluorescence microscopy after labelling with Fluor 488-alkyne. The [18F]4-N-alkyl or alkanoyl silane gemcitabine analogues were successfully synthesized using microscale and conventional silane-labeling radiochemical protocols. Preliminary positron-emission tomography (PET) imaging in mice showed the biodistribution of [18F]4-N-alkyl to have initial concentration in the liver, kidneys and GI tract followed by increasing signal in the bone.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29471120      PMCID: PMC5841594          DOI: 10.1016/j.ejmech.2018.02.017

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  47 in total

1.  Micro-chemical synthesis of molecular probes on an electronic microfluidic device.

Authors:  Pei Yuin Keng; Supin Chen; Huijiang Ding; Saman Sadeghi; Gaurav J Shah; Alex Dooraghi; Michael E Phelps; Nagichettiar Satyamurthy; Arion F Chatziioannou; Chang-Jin Kim; R Michael van Dam
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-30       Impact factor: 11.205

2.  Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer.

Authors:  Mallaredy Vandana; Sanjeeb K Sahoo
Journal:  Biomaterials       Date:  2010-09-20       Impact factor: 12.479

3.  Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.

Authors:  Jason T Lee; Dean O Campbell; Nagichettiar Satyamurthy; Johannes Czernin; Caius G Radu
Journal:  J Nucl Med       Date:  2012-02       Impact factor: 10.057

4.  18F-labeling of peptides by means of an organosilicon-based fluoride acceptor.

Authors:  Ralf Schirrmacher; Gerrit Bradtmöller; Esther Schirrmacher; Oliver Thews; Julia Tillmanns; Thomas Siessmeier; Hans G Buchholz; Peter Bartenstein; Björn Wängler; Christof M Niemeyer; Klaus Jurkschat
Journal:  Angew Chem Int Ed Engl       Date:  2006-09-11       Impact factor: 15.336

5.  IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.

Authors:  Federico Cividini; Daniela Nicole Filoni; Rossana Pesi; Simone Allegrini; Marcella Camici; Maria Grazia Tozzi
Journal:  Biochim Biophys Acta       Date:  2015-04-07

6.  Silicon-based chemistry: an original and efficient one-step approach to [18F]-nucleosides and [18F]-oligonucleotides for PET imaging.

Authors:  Jürgen Schulz; Delphine Vimont; Thomas Bordenave; Damien James; Jean-Marc Escudier; Michèle Allard; Magali Szlosek-Pinaud; Eric Fouquet
Journal:  Chemistry       Date:  2011-02-10       Impact factor: 5.236

7.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.

Authors:  J R Mackey; R S Mani; M Selner; D Mowles; J D Young; J A Belt; C R Crawford; C E Cass
Journal:  Cancer Res       Date:  1998-10-01       Impact factor: 12.701

Review 8.  Role of gemcitabine in cancer therapy.

Authors:  L Toschi; G Finocchiaro; S Bartolini; V Gioia; F Cappuzzo
Journal:  Future Oncol       Date:  2005-02       Impact factor: 3.404

9.  Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug.

Authors:  Sukhendu Maiti; Nayoung Park; Ji Hye Han; Hyun Mi Jeon; Jae Hong Lee; Sankarprasad Bhuniya; Chulhun Kang; Jong Seung Kim
Journal:  J Am Chem Soc       Date:  2013-03-12       Impact factor: 15.419

10.  High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.

Authors:  Quteba Ebrahem; Reda Z Mahfouz; Kwok Peng Ng; Yogen Saunthararajah
Journal:  Oncotarget       Date:  2012-10
View more
  4 in total

1.  Synthesis and 18F-radiolabeling of thymidine AMBF3 conjugates.

Authors:  Antonio A W L Wong; Jerome Lozada; Mathieu L Lepage; Chengcheng Zhang; Helen Merkens; Jutta Zeisler; Kuo-Shyan Lin; François Bénard; David M Perrin
Journal:  RSC Med Chem       Date:  2020-04-23

2.  4-N-Alkanoyl and 4-N-alkyl gemcitabine analogues with NOTA chelators for 68-gallium labelling.

Authors:  Jesse Pulido; Maria de Cabrera; Adam J Sobczak; Alejandro Amor-Coarasa; Anthony J McGoron; Stanislaw F Wnuk
Journal:  Bioorg Med Chem       Date:  2018-10-12       Impact factor: 3.641

Review 3.  1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.

Authors:  Khurshed Bozorov; Jiangyu Zhao; Haji A Aisa
Journal:  Bioorg Med Chem       Date:  2019-07-04       Impact factor: 3.641

4.  High-Efficiency Production of Radiopharmaceuticals via Droplet Radiochemistry: A Review of Recent Progress.

Authors:  Jia Wang; R Michael van Dam
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.